Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (3754)	10/9/1999 11:38:00 AM
From: rkrw	Read Replies (1) \| Respond to of 10280

Thanks V1. One problem is that they have only the nebulizer version on the market. So they're playing with maybe 20% of the total US albuterol market. _IF_they can break this market open with these Troff studies it should trickle down to the rest of the rollout when they reach market with the MDI/DPI as well as the smaller market syrup and tablets. Add in the potential for a better label, pediatric indications and it could start showing some solid potential. Its off to a slow start but I wouldn't rule out xopenex just yet.